Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Widely cited in recent published papers1, 2, 3, 4 - Detachin™ is proven to quickly deliver gentle detachment of a wide variety of adherent cells, including primary cell types and delicate culture systems, from any tissue culture plasticware. These papers involving primary immune cells, patient-derived cancer models, engineered mammalian lines and high-throughput screening systems, provide further…
Highly accomplished senior real estate executive leader and investment professional, Andy Creighton, joins Howard Group
Cambridge, 18th November 2025: Leading regional property investor and developer Howard Group, is delighted to announce the appointment of Andy Creighton as Group Property Director.
In his new role, Andy will be responsible for overseeing Howard Group’s property activities, including its investment, development and asset management functions. He will also be appointed to the Board of Directors and join the Executive Team.
Andy brings a long and…
Over four decades since its conception in 1980, Fragment-Based Drug Discovery (FBDD) has emerged as an innovative and efficient approach to modern drug development, showing advantages over traditional high-throughput screening (HTS) methods. By focusing on smaller, simpler molecules, FBDD provides a foundation for developing novel therapeutics, especially for challenging previously “undruggable” targets.
Historically, FBDD has led to several milestone achievements in drug development, with eight FDA-approved drugs and more than 50 compounds currently in clinical stages. The first FDA-…
Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.
Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
The collaboration brings together RxCelerate’s integrated drug discovery and development expertise with Constructive Bio’s proprietary…
The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
These treatments are a type of precision medicine, known as radiopharmaceuticals. Whilst…
Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Cambridge, UK, 17 November 2025: Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Dr Stephen Shuttleworth as Chief Scientific…
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
Under the collaboration, Mursla Bio’s AI Precision Medicine…
· Industry leader brings deep expertise across neurodegenerative disease therapeutics development
· Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB
Cambridge, UK, 11 November 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the…
San Diego, CA & Montpellier, FR – November 6, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership. This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
Understanding the challenges of early-stage development, Mabqi and Abzena formed…
SoluLyse™ from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells.
Based upon a proprietary non-ionic detergent formulation, with the SoluLyse™ reagent there is no need for time-consuming and cumbersome secondary treatment methods such as sonication or freeze thaw. The unique, mild SoluLyse™ formulation allows perforation of bacterial cell walls without denaturing proteins.
In addition, the SoluLyse™ reagent offers an up to ten-fold increase in the yield of soluble proteins when…